United Therapeutics

Andrew Fisher Joins Verona Pharma as General Counsel

Retrieved on: 
Monday, March 4, 2024

LONDON and RALEIGH, N.C., March 04, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces Mr. Andrew Fisher has today joined the Company as General Counsel, and member of the Executive Management Team.

Key Points: 
  • LONDON and RALEIGH, N.C., March 04, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces Mr. Andrew Fisher has today joined the Company as General Counsel, and member of the Executive Management Team.
  • Mr. Fisher is an accomplished lawyer with more than 25 years of experience in the life sciences industry.
  • He brings a wealth of legal and strategic expertise supporting global, pre-clinical and clinical development, manufacturing and commercialization including launching four pulmonary therapies.
  • Dr. Zaccardelli added: “We would like to thank Claire for her leadership and recognise her significant contributions to Verona Pharma’s successful development since its inception.

United Therapeutics Corporation to Present at the Leerink Partners Global Biopharma Conference 2024

Retrieved on: 
Tuesday, March 5, 2024

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that Patrick Poisson, Executive Vice President, Technical Operations, will provide an overview and update on the company’s operations during a fireside chat session at the Leerink Partners Global Biopharma Conference 2024 in Miami Beach, Florida.

Key Points: 
  • United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that Patrick Poisson, Executive Vice President, Technical Operations, will provide an overview and update on the company’s operations during a fireside chat session at the Leerink Partners Global Biopharma Conference 2024 in Miami Beach, Florida.
  • The session will take place on Tuesday, March 12, 2024, from 1:40 p.m. to 2:10 p.m., Eastern Daylight Time, and can be accessed via a live webcast on the United Therapeutics website at https://ir.unither.com/events-and-presentations .
  • An archived, recorded version of the session will be available approximately 24 hours after the session ends and can be accessed for 90 days.
  • We are the first publicly-traded biotech or pharmaceutical company to take the form of a public benefit corporation (PBC).

United Therapeutics Corporation to Present at the TD Cowen 44th Annual Health Care Conference

Retrieved on: 
Tuesday, February 27, 2024

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that Michael Benkowitz, President and Chief Operating Officer, will provide an overview and update on the company’s operations during a fireside chat session at the TD Cowen 44th Annual Health Care Conference in Boston.

Key Points: 
  • United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that Michael Benkowitz, President and Chief Operating Officer, will provide an overview and update on the company’s operations during a fireside chat session at the TD Cowen 44th Annual Health Care Conference in Boston.
  • An archived, recorded version of the session will be available approximately 24 hours after the session ends and can be accessed for 90 days.
  • At United Therapeutics, our vision and mission are one.
  • We are the first publicly-traded biotech or pharmaceutical company to take the form of a public benefit corporation (PBC).

United Therapeutics Commences Litigation to Ensure Fairness in the Drug Review Process

Retrieved on: 
Wednesday, February 21, 2024

United Therapeutics Corporation (Nasdaq: UTHR) announced today the commencement of litigation with the United States Food and Drug Administration (FDA).

Key Points: 
  • United Therapeutics Corporation (Nasdaq: UTHR) announced today the commencement of litigation with the United States Food and Drug Administration (FDA).
  • In the litigation, United Therapeutics alleges that the FDA mistakenly permitted Liquidia Corporation (Liquidia) to skirt longstanding FDA rules, precedents, and procedures on how pending drug approval applications are handled by the agency.
  • In doing so, the FDA inappropriately denied United Therapeutics its right to obtain a stay of Liquidia’s final approval until United Therapeutics’ pending patent infringement claim against Liquidia can be resolved.
  • United Therapeutics believes this distinction is critical to ensure the proper review and approval of new drug applications in a fair, equitable manner consistent with the FDA’s prior practices with which industry has complied for decades.

United Therapeutics Corporation to Report Fourth Quarter and Full Year 2023 Financial Results Before the Market Opens on Wednesday, February 21, 2024

Retrieved on: 
Wednesday, February 14, 2024

United Therapeutics Corporation (Nasdaq: UTHR), announced today that it will report its fourth quarter and full year 2023 financial results before the market opens on Wednesday, February 21, 2024.

Key Points: 
  • United Therapeutics Corporation (Nasdaq: UTHR), announced today that it will report its fourth quarter and full year 2023 financial results before the market opens on Wednesday, February 21, 2024.
  • United Therapeutics will host a public webcast Wednesday, February 21, 2024, at 9:00 a.m. Eastern Time.
  • The webcast will be accessible via United Therapeutics' website at https://ir.unither.com/events-and-presentations .
  • We are the first publicly-traded biotech or pharmaceutical company to take the form of a public benefit corporation (PBC).

Farm Management Canada’s Annual Agricultural Conference is Sowing the Seeds of Excellence

Retrieved on: 
Friday, January 26, 2024

OTTAWA, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Farm Management Canada held its annual Agricultural Excellence (AgEx) Conference in Guelph, Ontario welcoming farm management enthusiasts from across Canada to gather, learn and exchange knowledge and insights!

Key Points: 
  • OTTAWA, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Farm Management Canada held its annual Agricultural Excellence (AgEx) Conference in Guelph, Ontario welcoming farm management enthusiasts from across Canada to gather, learn and exchange knowledge and insights!
  • The agenda provided a diverse learning experience for participants, covering a multitude of farm business management topics.
  • During the annual Agricultural Excellence Banquet, Alberta's Steve Funk was recognized for his contribution to farm management excellence with the prestigious Wilson Loree Award.
  • Join Farm Management Canada in Abbotsford-Chilliwack, British Columbia for AgEx 2024 | November 19-21, 2024.

Liquidia Corporation Provides Update on New Drug Application for YUTREPIA™ (treprostinil) inhalation powder

Retrieved on: 
Thursday, January 25, 2024

The FDA informed the Company that it is confirming the process for adding the PH-ILD indication as an amendment to the NDA for YUTREPIA.

Key Points: 
  • The FDA informed the Company that it is confirming the process for adding the PH-ILD indication as an amendment to the NDA for YUTREPIA.
  • The FDA did not request any additional clinical data to support the NDA and did not issue a new PDUFA goal date.
  • As communicated by the tentative approval to treat PAH, YUTREPIA has already met the regulatory standards for quality, safety and efficacy.
  • In July 2023, Liquidia filed an amendment to its New Drug Application for YUTREPIA, seeking to add PH-ILD to the label.

EHang Holdings Limited investors: Please contact the Portnoy Law Firm to recover your losses; February 2, 2024 deadline

Retrieved on: 
Wednesday, January 24, 2024

​LOS ANGELES, Jan. 23, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises EHang Holdings Limited (NASDAQ: EH) investors that a lawsuit filed on behalf of investors that purchased EHang securities between January 20, 2022 and November 6, 2023, inclusive (the “Class Period”)

Key Points: 
  • The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
  • The lawsuit contends that when the truth was revealed to the market, investors incurred losses.
  • The Portnoy Law Firm represents investors in pursuing claims caused by corporate wrongdoing.
  • The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors.

Maryland Organizations Inspire Inclusivity and Economic Development Through Awards, Programming, and More

Retrieved on: 
Friday, January 19, 2024

BALTIMORE, Jan. 19, 2024 /PRNewswire-PRWeb/ -- The Maryland Marketing Partnership, which helps drive Maryland's branding and marketing efforts to attract businesses, create jobs, and grow the state's economy, today shared a summary of the latest news from companies and organizations that are part of the partnership.

Key Points: 
  • "We celebrate the continued achievements of our Maryland businesses, helping us to drive economic development, grow jobs, attract and retain talented workers, and contribute to an outstanding climate for business in our state."
  • His commitment to maintaining an inclusive workplace where associates are supported and inspired continues to grow a thriving workplace environment.
  • Read more: https://shorturl.at/mortL
    TEDCO , Maryland's economic engine for technology companies, continues to invest in Maryland technology startups including PediaMetrix, Rendr, VirgilHR, and more.
  • As a proactive driver of economic development in the Baltimore region, Tradepoint Atlantic is dedicated to making successful strides toward a more inclusive and thriving business community.

Liquidia Corporation Files Response to United Therapeutics Lawsuit and Files Counterclaims

Retrieved on: 
Monday, January 8, 2024

11,826,327 (the ‘327 patent) in association with Liquidia’s New Drug Application (NDA) for YUTREPIA™ (treprostinil) inhalation powder.

Key Points: 
  • 11,826,327 (the ‘327 patent) in association with Liquidia’s New Drug Application (NDA) for YUTREPIA™ (treprostinil) inhalation powder.
  • Simultaneously, Liquidia filed counterclaims against UTHR seeking a declaration that all asserted claims of the ‘327 patent are not infringed, are invalid and are unenforceable.
  • Furthermore, the counterclaims summarize certain publications, references and information that UTHR failed to submit to the United States Patent and Trademark Office (USPTO) during the prosecution of the ‘327 patent.
  • Liquidia has also asserted that these same references and information, as set forth in the counterclaims, also render the claims of the ‘327 patent invalid.